Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis

NCT05878938 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05878938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05878938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
June 26, 2023
Completion date
July 19, 2024
Enrollment
61 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia a, haemophilia a with inhibitors